��������

Lori Houle is the senior vice president of quality at Neumora. A bacteriologist/molecular biologist by training, Lori brings to Neumora more than 30 years of experience in analytical development, quality control and quality assurance.

Prior to Neumora, Lori acted as the vice president of global quality at Vir Biotechnology, where she successfully led the development of compliance systems and strategy across three different platforms: monoclonal antibodies, siRNA and live viral vaccines. There, Lori and her team oversaw the manufacturing of seven drug products supporting nine global and one U.S. clinical studies in under four years, including two COVID-19 molecules. Prior to Vir, Lori held leadership roles at Dermira, Sarepta Therapeutics, Eragen Bioscienses, Anteco Pharma, PPD and Wyeth (SPL). She oversaw all aspects of compliance, ultimately leading to the successful launch of the drugs Qbrexza, CIMZIA (UCB Partnership) and EXONDYS 51.

Lori holds degrees in bacteriology and medical microbiology from University of Wisconsin Madison and an MBA from Keller.